Skip to main content
Shanghai ZJ Bio-Tech Co., Ltd logo

Shanghai ZJ Bio-Tech Co., Ltd — Investor Relations & Filings

Ticker · 688317 ISIN · CNE100005DB6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-10-23 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688317

About Shanghai ZJ Bio-Tech Co., Ltd

https://m.liferiver.com.cn/

Shanghai ZJ Bio-Tech Co., Ltd., operating under the brand Liferiver, specializes in the development, manufacture, and distribution of molecular diagnostic reagents and equipment. The company’s core expertise lies in real-time PCR technology, providing a comprehensive portfolio of over 400 diagnostic kits. These solutions target a broad spectrum of infectious diseases, including viral hepatitis, respiratory infections, sexually transmitted diseases, and zoonotic pathogens. Beyond clinical diagnostics, the company offers specialized kits for food safety testing and veterinary health monitoring. Its products are utilized by clinical laboratories, hospitals, and public health institutions worldwide. Many diagnostic assays have achieved international recognition through CE marking and World Health Organization (WHO) listings. The company focuses on delivering high-sensitivity, high-specificity molecular tools to facilitate rapid pathogen detection and disease management.

Recent filings

Filing Released Lang Actions
之江生物：关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the top ten shareholders and top ten unrestricted shareholders of Shanghai Zhijiang Bio-Technology Co., Ltd. in relation to a share repurchase plan approved by the board. It lists shareholder names, share quantities, and percentages. The document references a share repurchase scheme and provides detailed shareholding information but does not contain financial statements or earnings data. This fits the category of a Transaction in Own Shares (POS) report, which covers company buybacks or sales of its own shares.
2025-10-23 Chinese
之江生物：第五届董事会第十六次会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a board meeting resolution announcement from Shanghai Zhijiang Bio-Technology Co., Ltd. It details the board's approval of a share repurchase plan, including specifics on the amount, price, and purpose of the buyback. The document is short (1015 characters) and focuses on the board's decision regarding share repurchase. It is not a full financial report, audit, or earnings release. It is not a report publication announcement since it contains substantive content about the board resolution. The content fits the category of Transaction in Own Shares (POS), which covers announcements of company buybacks or sales of its own shares.
2025-10-16 Chinese
之江生物：关于2025年第三次以集中竞价交易方式回购股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Shanghai Zhijiang Bio-Technology Co., Ltd. regarding a share repurchase plan through centralized bidding. It includes specifics such as the amount of shares to be repurchased, price limits, funding sources, purpose (employee stock ownership plan or equity incentives), board approval details, risk factors, and authorization for management to execute the plan. The document is not a financial report, earnings release, or management discussion but a formal announcement of a share buyback program. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back its own shares. The document length and content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2025-10-16 Chinese
之江生物：关于开立募集资金专户并签订募集资金专户监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Zhijiang Bio-technology Co., Ltd. regarding the opening of a special account for raised funds and the signing of a supervision agreement for the raised funds account. It details the background of the fundraising, the account opening, and the regulatory agreement signed with the bank and securities company. The document is relatively short (2496 characters) and focuses on the procedural and regulatory aspects of managing the raised funds, not on financial results or detailed financial statements. It is not a full financial report but an announcement related to capital raising and fund management. Therefore, it fits best under Capital/Financing Update (CAP).
2025-09-26 Chinese
之江生物：关于召开2025年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 half-year performance explanation meeting (业绩说明会) for investors. It references that the company's 2025 half-year report was already published on August 29, 2025, and this meeting is to discuss and answer questions about that report. The document does not contain actual financial data or detailed financial analysis itself, but rather provides logistical information about the upcoming investor call. This fits the definition of an Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, specifically an earnings explanation meeting. The document length is short and it is not a report publication announcement or a regulatory filing. Therefore, the best classification is Investor Presentation (IP).
2025-09-23 Chinese
之江生物：关于自愿披露公司产品列入WHO应急使用清单的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure that its product has been included in the WHO Emergency Use Listing (EUL). It discusses the product details, impact on the company, and associated risks. The document is short (1106 characters) and does not contain financial statements or detailed financial data. It is an announcement about a regulatory or product status update rather than a financial report or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others related to financial performance. It is a regulatory announcement about product approval and risk disclosure, which fits best under Regulatory Filings (RNS).
2025-09-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.